Cover Image
市場調查報告書

Grunenthal GmbH - 產品平台檢討

Grunenthal GmbH - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 219819
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
Grunenthal GmbH - 產品平台檢討 Grunenthal GmbH - Product Pipeline Review - 2016
出版日期: 2016年07月30日 內容資訊: 英文 47 Pages
簡介

Grunenthal GmbH 是以研究為主要著眼點的全球規模製藥公司。尤其擅長於疼痛治療、以創新手法來配合已經實証的有效成分,開發、製造並銷售疼痛治療藥。

本報告提供Grunenthal GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Grunenthal GmbH的基本資料

Grunenthal GmbH概要

  • 主要資訊
  • 企業資料

Grunenthal GmbH:R&D概要

  • 主要的治療範圍

Grunenthal GmbH:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Grunenthal GmbH:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Grunenthal GmbH:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Grunenthal GmbH:藥物簡介

  • cebranopadol
  • tapentadol hydrochloride
  • tapentadol hydrochloride ER
  • GRT-6010
  • GRT-6011
  • Small Molecule 1 for Pain
  • Small Molecule 2 for Pain
  • GRTTA-2210
  • RO-656570
  • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
  • Small Molecule-3 for Pain
  • Small Molecule for Pain
  • (oxycodone + naloxone)
  • GRT-6006

Grunenthal GmbH:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Grunenthal GmbH:最近的開發平台趨勢

Grunenthal GmbH:暫停中的計劃

Grunenthal GmbH:企業發表

Grunenthal GmbH:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08104CDB

Summary

Global Markets Direct's, 'Grunenthal GmbH - Product Pipeline Review - 2016', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Grunenthal GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Grunenthal GmbH
  • The report provides overview of Grunenthal GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Grunenthal GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Grunenthal GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Grunenthal GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Grunenthal GmbH's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Grunenthal GmbH Snapshot
    • Grunenthal GmbH Overview
    • Key Information
    • Key Facts
  • Grunenthal GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Grunenthal GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Grunenthal GmbH - Pipeline Products Glance
    • Grunenthal GmbH - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Grunenthal GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Grunenthal GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Grunenthal GmbH - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Grunenthal GmbH - Drug Profiles
    • cebranopadol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tapentadol hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRTTA-2210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RO-656570
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 3 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate KCNQ and TSPO for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Grunenthal GmbH - Pipeline Analysis
    • Grunenthal GmbH - Pipeline Products by Target
    • Grunenthal GmbH - Pipeline Products by Route of Administration
    • Grunenthal GmbH - Pipeline Products by Molecule Type
    • Grunenthal GmbH - Pipeline Products by Mechanism of Action
  • Grunenthal GmbH - Recent Pipeline Updates
  • Grunenthal GmbH - Dormant Projects
  • Grunenthal GmbH - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • axomadol
      • lexanopadol
  • Grunenthal GmbH - Company Statement
  • Grunenthal GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Grunenthal GmbH, Key Information
  • Grunenthal GmbH, Key Facts
  • Grunenthal GmbH - Pipeline by Indication, 2016
  • Grunenthal GmbH - Pipeline by Stage of Development, 2016
  • Grunenthal GmbH - Monotherapy Products in Pipeline, 2016
  • Grunenthal GmbH - Partnered Products in Pipeline, 2016
  • Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2016
  • Grunenthal GmbH - Phase III, 2016
  • Grunenthal GmbH - Phase II, 2016
  • Grunenthal GmbH - Phase I, 2016
  • Grunenthal GmbH - Preclinical, 2016
  • Grunenthal GmbH - Discovery, 2016
  • Grunenthal GmbH - Unknown, 2016
  • Grunenthal GmbH - Pipeline by Target, 2016
  • Grunenthal GmbH - Pipeline by Route of Administration, 2016
  • Grunenthal GmbH - Pipeline by Molecule Type, 2016
  • Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016
  • Grunenthal GmbH - Recent Pipeline Updates, 2016
  • Grunenthal GmbH - Dormant Developmental Projects,2016
  • Grunenthal GmbH - Discontinued Pipeline Products, 2016
  • Grunenthal GmbH, Other Locations
  • Grunenthal GmbH, Subsidiaries

List of Figures

  • Grunenthal GmbH - Pipeline by Top 10 Indication, 2016
  • Grunenthal GmbH - Pipeline by Stage of Development, 2016
  • Grunenthal GmbH - Monotherapy Products in Pipeline, 2016
  • Grunenthal GmbH - Partnered Products in Pipeline, 2016
  • Grunenthal GmbH - Pipeline by Target, 2016
  • Grunenthal GmbH - Pipeline by Route of Administration, 2016
  • Grunenthal GmbH - Pipeline by Molecule Type, 2016
  • Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016
Back to Top